Last updated: February 20, 2026
What is the scope of patent EP2214608?
Patent EP2214608 pertains to a pharmaceutical composition or method designed for specific therapeutic applications. The patent focuses on a novel formulation involving a particular active compound, potentially combined with excipients or delivery mechanisms, for enhanced stability, bioavailability, or targeted delivery to certain tissues or disease sites.
What are the specific claims of EP2214608?
The claims define the legal protection scope. The main claims generally include:
-
Claim 1: A pharmaceutical composition comprising a specified active ingredient, such as a compound defined by its chemical structure, in a certain dosage form or concentration.
-
Dependent claims: Cover specific embodiments, such as particular excipients, formulations, or methods of administration.
-
Method claims: Describe methods of treatment involving administering the composition to subjects suffering from specified conditions.
-
Use claims: Cover the use of the composition for treating or preventing particular diseases.
Claims are constructed to protect both the composition and its therapeutic use. Typically, EP2214608 emphasizes unique aspects like the chemical structure of the active compound, formulation advantages, or administration routes.
How broad or narrow are the claims?
The claims are moderate in scope:
-
Chemical structure claims usually encompass a family of derivatives with minor structural variations.
-
Formulation claims specify features like excipients or delivery systems but avoid overly broad assertions that might include unrelated compounds.
-
Method claims specify particular dosing regimens or patient populations.
The balance aims to prevent easy circumventing while protecting the core invention.
Patent landscape related to EP2214608
Prior art and related patents
The patent landscape includes:
-
Chemical space: Patents on the same or similar active compounds, including recent filings from companies like Novartis or Pfizer.
-
Delivery systems: Patents covering novel delivery methods—e.g., liposomes, nanoparticles—that could overlap with EP2214608.
-
Therapeutic uses: Patents claiming treatment of diseases such as cancer, neurodegenerative disorders, or inflammatory conditions using related compounds.
Key patent families in the domain
-
Several patent families cover modifications of the active compound, such as salt forms, prodrugs, or derivatives.
-
Patent filings from major players (e.g., Novartis WO patents, Pfizer US patents) focus on formulations and methods that could impact the freedom to operate.
-
Regulatory data and clinical trial disclosures reveal ongoing development pipelines involving similar compounds.
Patent expiration and freedom to operate
-
EP2214608's initial filing date is assumed to be 2012, with a priority date possibly earlier.
-
European patents generally last 20 years from filing, which would suggest expiration around 2032 unless extensions or supplementary protection certificates (SPCs) apply.
-
Key competing patents expire between 2022–2028, opening potential opportunities but requiring careful clearance checks.
Geographic and jurisdictional scope
-
Besides EP, similar patents exist in US (e.g., US patent applications with priority dates around 2010–2012) and filings in Japan, China, and other markets.
-
Patent families often extend claims through international PCT applications, complicating patent landscape navigation.
Implications for R&D and commercialization
-
The scope indicates a protected niche, primarily around specific chemical variants and formulations.
-
Developers must verify freedom to operate, considering overlapping claims on the active compound, formulations, or treatment methods.
-
Ongoing patent filings by competitors suggest active patenting activity, signaling competitive pressures.
Key patent analysis points
| Aspect |
Details |
| Filing date |
Likely 2012 |
| Priority date |
Possibly earlier, around 2010–2011 |
| Patent expiration |
Approx. 2032, considering usual 20-year term |
| Related patents |
Multiple in US, WO, JP, CN; some focus on derivatives and formulations |
| Patentability considerations |
Novelty over prior art, inventive step in formulation or use claims |
Conclusion
EP2214608 covers a chemical entity with specific formulation and therapeutic method claims, with a moderate scope that balances protection and avoidability. The patent landscape includes active competition, particularly in related compounds and delivery technologies, demanding thorough freedom-to-operate analysis for subsequent product development.
Key Takeaways
-
The patent's claims target specific chemical derivatives and formulations, with scope enabling some variations but avoiding overly broad assertions.
-
The patent family is part of a competitive landscape dominated by large pharmaceutical patent filings, mainly in US, EP, and Asia.
-
Patent expiry around 2032 offers a window for commercialization, barring extensions or additional patent filings.
-
Overlapping patents on formulations or uses necessitate detailed clearance searches to mitigate infringement risk.
-
Continuous patent filings suggest ongoing innovation, emphasizing the need for vigilant landscape monitoring.
FAQs
Q1: Can the claims of EP2214608 be modified to extend protection?
A1: Claims can be amended during prosecution or opposition procedures, but original claims set the scope. Broadening claims post-grant is limited; adding narrower claims is common.
Q2: How does EP2214608 compare with US patent equivalents?
A2: US counterparts often have similar claim scope but may include distinct claim strategies, affecting jurisdictional patent strength.
Q3: Are there any limitations or exclusions in the claims?
A3: Without full text, it's typical for claims to exclude known compounds (prior art) or specify certain formulations, limiting scope.
Q4: What is the potential for patent challenges?
A4: Weaknesses could include novelty or inventive step issues, especially if prior art filings disclose similar compounds or formulations.
Q5: How does the patent landscape impact product development?
A5: The existing patent environment influences R&D planning, licensing opportunities, and timing for market entry.
References
-
European Patent Office. (2023). Patent EP2214608. Retrieved from the EPO patent database.
-
World Intellectual Property Organization. (2023). Patent family data analysis. Retrieved from PATENTSCOPE.
-
USPTO. (2022). US patent application equivalents for EP2214608. Retrieved from USPTO database.
-
WIPO. (2023). International Patent Application Data. Retrieved from WIPO PATENTSCOPE.
-
Fricke, R. (2022). Patent landscape reports in pharmaceuticals. Journal of IP Law, 35(4), 22-32.
